Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 6
2001 3
2002 3
2003 2
2004 2
2005 3
2006 3
2007 1
2008 4
2009 3
2010 1
2011 5
2012 3
2013 4
2014 3
2015 1
2016 5
2017 6
2018 10
2019 11
2020 8
2021 7
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

89 results
Results by year
Filters applied: . Clear all
Page 1
Haemodynamic definitions and updated clinical classification of pulmonary hypertension.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Simonneau G, et al. Eur Respir J. 2019 Jan 24;53(1):1801913. doi: 10.1183/13993003.01913-2018. Print 2019 Jan. Eur Respir J. 2019. PMID: 30545968 Free PMC article. Review.
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) 25 mmHg at rest, measured by right heart catheterisation. ...Prospective trials are required t …
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defin …
International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension.
Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA, Sitbon O, Sokol RJ. Krowka MJ, et al. Transplantation. 2016 Jul;100(7):1440-52. doi: 10.1097/TP.0000000000001229. Transplantation. 2016. PMID: 27326810
Two distinct pulmonary vascular disorders, hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) may occur as a consequence of hepatic parenchymal or vascular abnormalities. ...Definitions/Diagnostic criteria; II. Hepatopulmonary syndrome; III. Po
Two distinct pulmonary vascular disorders, hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) may occur as …
Hepatopulmonary Syndrome and Portopulmonary Hypertension: Pulmonary Vascular Complications of Liver Disease.
Del Valle K, DuBrock HM. Del Valle K, et al. Compr Physiol. 2021 Oct 12;11(4):3281-3302. doi: 10.1002/cphy.c210009. Compr Physiol. 2021. PMID: 34636408
Pulmonary vascular disease is a frequent complication of chronic liver disease and portal hypertension, affecting up to 30% of patients. There are two distinct pulmonary vascular complications of liver disease: hepatopulmonary syndrome (HPS) and portopulmonary hy
Pulmonary vascular disease is a frequent complication of chronic liver disease and portal hypertension, affecting up to 30% of patien …
Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Cardiovascular, Endocrine, Hematologic, Pulmonary, and Renal Considerations.
Nanchal R, Subramanian R, Karvellas CJ, Hollenberg SM, Peppard WJ, Singbartl K, Truwit J, Al-Khafaji AH, Killian AJ, Alquraini M, Alshammari K, Alshamsi F, Belley-Cote E, Cartin-Ceba R, Dionne JC, Galusca DM, Huang DT, Hyzy RC, Junek M, Kandiah P, Kumar G, Morgan RL, Morris PE, Olson JC, Sieracki R, Steadman R, Taylor B, Alhazzani W. Nanchal R, et al. Crit Care Med. 2020 Mar;48(3):e173-e191. doi: 10.1097/CCM.0000000000004192. Crit Care Med. 2020. PMID: 32058387
Pulmonary Complications of Portal Hypertension.
Cartin-Ceba R, Krowka MJ. Cartin-Ceba R, et al. Clin Liver Dis. 2019 Nov;23(4):683-711. doi: 10.1016/j.cld.2019.06.003. Epub 2019 Aug 9. Clin Liver Dis. 2019. PMID: 31563218 Review.
The most common pulmonary complications of chronic liver disease are hepatic hydrothorax, hepatopulmonary syndrome, and portopulmonary hypertension. Hepatic hydrothorax is a transudative pleural effusion in a patient with cirrhosis and no evidence of underlying card …
The most common pulmonary complications of chronic liver disease are hepatic hydrothorax, hepatopulmonary syndrome, and portopulmonary
Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, Kim NH, Martin N, Savale L, Krowka M. Sitbon O, et al. Lancet Respir Med. 2019 Jul;7(7):594-604. doi: 10.1016/S2213-2600(19)30091-8. Epub 2019 Jun 6. Lancet Respir Med. 2019. PMID: 31178422 Clinical Trial.
BACKGROUND: No dedicated randomised clinical trials have evaluated therapies for pulmonary arterial hypertension in patients with portopulmonary hypertension. The endothelin receptor antagonist macitentan has demonstrated long-term efficacy in pulmonary arter …
BACKGROUND: No dedicated randomised clinical trials have evaluated therapies for pulmonary arterial hypertension in patients with …
Portopulmonary hypertension.
Krowka MJ. Krowka MJ. Semin Respir Crit Care Med. 2012 Feb;33(1):17-25. doi: 10.1055/s-0032-1301731. Epub 2012 Mar 23. Semin Respir Crit Care Med. 2012. PMID: 22447257 Review.
Portopulmonary hypertension (POPH) refers to the presence of pulmonary arterial hypertension (PAH) in patients with portal hypertension. Pulmonary hypertension in patients with liver disease or portal hypertension can be due to multiple m
Portopulmonary hypertension (POPH) refers to the presence of pulmonary arterial hypertension (PAH) in patients with por
Portopulmonary hypertension.
Cartin-Ceba R, Krowka MJ. Cartin-Ceba R, et al. Clin Liver Dis. 2014 May;18(2):421-38. doi: 10.1016/j.cld.2014.01.004. Epub 2014 Feb 25. Clin Liver Dis. 2014. PMID: 24679504 Review.
Portopulmonary hypertension (POPH) is the presence of pulmonary arterial hypertension in patients with portal hypertension. ...
Portopulmonary hypertension (POPH) is the presence of pulmonary arterial hypertension in patients with portal hypert
Portopulmonary hypertension.
Golbin JM, Krowka MJ. Golbin JM, et al. Clin Chest Med. 2007 Mar;28(1):203-18, ix. doi: 10.1016/j.ccm.2006.11.004. Clin Chest Med. 2007. PMID: 17338936 Review.
These pulmonary vascular complications range from the hepatopulmonary syndrome, which is characterized by intrapulmonary vascular dilatations, to portopulmonary hypertension (POPH), which is characterized by an elevated pulmonary vascular resistance as a consequence …
These pulmonary vascular complications range from the hepatopulmonary syndrome, which is characterized by intrapulmonary vascular dilatation …
89 results